Project Interloper

CIA STARGATE release

CIA-RDP96-00788R001500110014-0

Opens with: 1. AMENDMENT/MODIFICATION NO

Warning: text for all documents has not been verified. Errors are possible. Check the original by document ID on CREST.

5 pages, machine transcribed from the CIA’s released scan.

AMLADIMENT 81 CONTRACT
EXCEPTION TO SF 30, APPROVED BY NARS 5/79
STANI ARD FORM 30, JULY 1966
. GENERAL SERVICES ADMINISTRATIO
FED: PROC. REG. (4) CFR
ApprovedAMER.MENTZOBSOLICITAFORPROLIFICROOBR9811CONTRACT
PAGE
1
OF
5
1. AMENDMENT/MODIFICATION NO.
P00002
2. EFFECTIVE DATE
30SEP81
3. REQUISITION/PURCHASE REQUEST NO.
1208/5702/81
4. PROJECT NO. (1/ applicable)
CODE
S0507A
AMEND F4 81
CONTRACT
7. CONTRACTOR
NAME AND ADDRESS
CODE
03652
FACILITY CODE.
AMENDMENT OF
SOUCITATION NO.
DATED
(See block 9)
MODIFICATION OF
CONTRACT/ORDER NO.
MDA903-81-C-0292
DATED
06APR81
(See block 11)
9. THIS BLOCK APPLIES ONLY TO AMENDMENTS OF SOLICITATIONS
The above numbered solicitation is amended as set forth in block 12.
The hour and date specified for receipt of Offers
is extended,
is not extended.
Offerors must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation, or as amended, by one of the following methods:
(a) By signing and returning _.
copies of this amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram
which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE ISSUING OFFICE PRIOR TO THE HOUR AND
DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If, by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram
or letter, provided such telegram or letter mokes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
10. ACCOUNTING AND APPROPRIATION DATA (If required)
ACRN:
AB 2112020 25-2037 P381321.03250-2572 S18128 2P29
$189,892.00
11. THIS BLOCK APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS
(a)
This Change Order is issued pursuant to
The Changes set forth in black 12 are made to the above numbered contract/order.
(b)
The above numbered controct/order is modified to reflect the administrative changes (such as changes in paying office, appropriation data, etc.) set forth in block 12.
(c)
This Supplemental Agreement is entered into pursuant to authority of
10 U.S.C. 2304 (a) (11)
It modifies the above numbered contract as set forth in block 12.
12. DESCRIPTION OF AMENDMENT/MODIFICATION
A. Delete any and all references to Contract No. MDA903-81-C-0292 and substitute therefor
Contract No. MDA908-81-C-0004.
B. Add the following as task number 2.1.10 to the Statement of Work (Classified) dated
19MAR 81:
(U) 2.1.10 Continue development and evaluation of CRV training program.
C. Add task numbers 2.1 and 2.2 of the Contractor's technical proposal number ESU 81-60
(Classified), dated 23MAR81, to the Statement of Work ( Classified) dated 19MAR81.
These tasks shall be remumbered 2.3 and 2.4 respectively.
D. Add an additional paragraph or section to the quarterly and final reports specified
in paragraph C.2 of the contract to cover the tasks added by this modification.
E. Add the following as paragraph H.9 of the contract :
(continued )
Except as provided herein, oll terms and conditions of the document referenced in block 8, as heretofore changed, remain unchanged and in full force and effect.
13.
CONTRACTOR/OFFEROR IS NOT REQUIRED
TO SIGN THIS DOCUMENT
CONTRACTOR/OFFEROR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN
2 COPIES TO ISSUING OFFICE
14. NAME OF CONTRA CTOR/OFFEROR
Amand land
17. UNITED STATES OF AMERICA.
Ban L. McVa
BY
ignature df Contreding Offjon)
15. NAME OF TITLE OF SIGNER (Type or print)
Spencer Floyd
Director, ContractApproved For Release ??
16. DATE SIGNED
18. NAME OF CONTRACTING OFFICER (Type or print )
9/00 10 9/09 : GARDE2600788R001500110014-0
19. DATE SIGNED
81SEP29
30-101-20
CODE
HIASA7
5. ISSUED BY
Virginia Contracting Activity
ATTN: RS-Q2
Washington, DC 20301
SRI International
333 Ravenswood Avenue
Menlo Park, CA 94025
(Street, city,
county, state,
and ZIP
Code)
L
6. ADMINISTERED BY (I/ other than bleck 5)
DCASMA San Francisco
1250 Bayhill Drive
San Bruno, CA 94066
i
BY
(Signature of person autorized to sign)
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
Contract MDA903-81-C-0292
Modification P00002
(New Contract MDA908-81C-0004)
Page 2 of 5
H- 9 USE OF HUMAN SUBJECTS (1978 Aug)
(a) .The following definitions are used in this clause:
(1) At risk means that the human subject may be exposed to the
possibility of harm - physical, biological, psychological, sociological, or
other - as a consequence of an act or omission that goes beyond the applica-
tion of those established and accepted methods or procedures which are in his
best interests, or that increases ordinary risks of daily life, including the
recognized risks inherent in his chosen occupation or field of service.
(2) Human Subject means any human being who, knowingly or unkowingly,
is subjected to an act or omission, whether at risk or not, the object of which
is to contribute to knowledge to be gained as a part of work to be performed under
the scope of this contract.
(b) The Contractor, before undertaking to perform any study involving
human subjects, whether at risk or not, shall insure that the following minimum
conditions are complied with:
(1) The proposed study has been reviewed and approved by a committee
meeting the requirements set forth in Chapter 46 of Title 45 of the Code of
-Federal Regulations.
(2) The number of human subjects used will be kept to the minimum
number that will reasonably achieve the required results.
(3) The study must be such as to contribute significantly to scientific
knowledge and have reasonable prospects of yielding important results essential to
an Army research program.
(4) The study will be conducted only by persons possessing the requisite
scientific qualifications. The highest degree of skill and care will be required
during all stages of study of persons who conduct or assist in the study.
(5) The human subject will be informed that at any time during the
course of his participation he has the right to revoke his consent and withdraw
from participation without prejudice to himself.
(6) Participation by subjects will be immediately terminated if it sub-
cequently appears that the risk to the subjects is significantly greater than
anticipated at the time review and approval was granted.
(7) There shall be no greater intrusion into the privacy of the human
subject than is absolutely necessary for the conduct of the study involved. Ex-
cept for the submission of reports and other data required by this contract, any
information obtained about human subjects as a result of their participation shall
be held as confidential as the law allows.
(8) The study will be conducted so as to avoid all unnecessary physical
or mental suffering or injury.
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
( continuea )
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
1
Contract MDA903-81-C-0292
Modification P00002
(New Contract MDA908-81-C-0004)
Page 3 of 5
(9) No study will be conducted if there is any inherent reason to believe
that death or disabling injury is likely to occur. Sufficient animal or laboratory
experiments, or other evaluations, must have been completed to give assurance of
acceptable risks prior to the use of human subjects.
(10) The degree of risk to be taken will never exceed that which is
justified by the benefit to the subject and/or the humanitarian importance of
the knowledge to be gained.
(11) A physician will be responsible for the medical care of subjects.
Even if not the project leader, the physician will have authority to terminate
the study at any time that he believes death, injury or harm is likely to result.
(12) Proper preparations will be made, and adequate facilities provided,
to protect the subject against all foreseeable possibilities of injury, disability,
or death. This includes but is not limited to hospitalization and medical treatmen
as may be required. In addition, all apparatus and instruments necessary to deal
with likely emergency situations will be available.
(13) Human subjects will have no physical or mental conditions which will
make participation more hazardous for them than it would be for normal healthy
persons, unless such condition is a necessary prerequisite for the particular
study involved. In any such case, the use of mman subjects with such pre-existing
conditions must have been specifically described and justified in the scope of the
work to be performed under this contract.
(14) The scientifically qualified person conducting the study, and each
member of his research team, will be prepared to terminate the subject's partici-
pation at any stage if he has reason to believe, in the exercise of the good faith,
superior skill, and careful judgment required of him, that continuation is likely
to result in injury, disability, or death to the human subject.
(c) The Contractor, before permitting any person to participate as a human
subject, whether at risk or not, shall insure that the following minimum conditions
are complied with:
(1) Legally effective informed consent will be obtained by adequate
and appropriate methods in accordance with the provisions of this clause.
(2) All consent must be voluntary. It must be the knowing consent of
the individual or his legally authorized representative, so situated as to be able
to exercise free power of choice without there having been any use of force, fraud,
deceit, duress, constraint, coercion, or lawful or improper inducement. The ele-
ments of information necessary to such consent include:
(1) A fair explanation of the procedures to be followed, and their
purposes, including identification of any procedures which are experimental.
(ii) A description of any attendant discomforts or risks reasonably
to be anticipated.
( continued )
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
Contract MDA903-81-C-0292
Modification PO0002
(New Contract No. MDA908-81-C-0004)
Page 4 of 5
(iii) A description of any benefits reasonably to be anticipated.
(iv) A disclosure of any appropriate alternative procedures that
might be advantageous to the subject.
(v) An offer to answer any questions concerning the procedure.
(vi) An instruction that the subject is free to revoke his consent
and to discontinue participation at any time without prejudice to himself.
(d) Exculpatory language through which the subject is made to waive, or
-
appear to waive, any of his legal rights, including any release from liability
for negligence, is prohibited.
(e) Prior consent by a subject or his legally authorized representative
shall be obtained in all cases. Such consent shall be in writing whenever it
is reasonably possible to do so. The consent form may be read to the subject
or his legally authorized representative, but in any event he or his legally
authorized representative must be given adequate opportunity to read it and to
ask questions they might have. This consent form should then be signed by the
subject or his legally authorized representative and by a witness not directly
involved in the study. Oral consent may be used only when it has been specifi-
cally described and justified in the scope of the work to be performed under
this contract or approved in writing by the contracting officer. When so author-
ized and used, oral consent is subject to all the same standards as apply to
written consent, except that the signature of the subject or his legally author-
ized representative is not required.
(f) Prior to conduct of the study, the contractor shall submit for approval
to the contracting officer a detailed description of the means by which informed
consent will be obtained, to include any forms to be used. Upon completion of the
study, the contractor will submit to the contracting officer detailed report demon-
strating compliance with paragraph (c), to include copies of the written consent if
such was obtained.
(g) The Contractor shall not undertake to conduct either the clinical
pharmacology or clinical trails of an investigational drug unless this contract
contains the clause entitled "Clinical Study of Investigational Drugs."
(h) Prisoners of war will not be used under any circumstances.
F.
Add the following as paragraph H.10 of the contract:
H. 10
All persons participating as human subjects, as defined by paragraph
H.9(a) (2) hereof, shall be known to possess the abilities and qualities
which will be observed and analyzed during the conduct of this contract.
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
1
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0
Contract No. MDA903-81-C-0292
Modification P00002
(New Contract No. MDA908-81-C-0004)
Page 5 of 5
G.
Military security requirements in the performance of contract MDA908-81-C-0004
as modified shall be maintained in accordance with the revised DD Form 254
attached hereto. The highest classification involved in the performance
of this contract as modified is TOP SECRET.
SGFOIA2
Approved For Release 2003/09/09 : CIA-RDP96-00788R001500110014-0

Follow along

New documents and dispatches as they publish. The newsletter is the one place to keep up.